Loading patent…
AssigneeGenzyme Corporation
InventorsClark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
Estimating the term…
The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
A binding polypeptide comprising at least one modified glycan comprising at least one moiety of Formula (IV):
2-22. (canceled)
A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of a binding polypeptide comprising:
25-26. (canceled)
28-33. (canceled)
A method of treating a subject in need thereof, the method comprising administering to the subject an effective amount of a binding polypeptide comprising:
A method of treating a subject in need thereof, the method comprising administering to the subject an effective amount of a binding polypeptide comprising:
Dependencies are inferred from the claim text.